Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background:
Atrial fibrillation (AF) is the most common arrhythmia, significantly contributing to complications such as stroke, heart failure, dementia, and increased mortality. Catheter ablation is widely used for treatment, but recurrence rates range from 15-50% within 12 months post-procedure. Conventional intermittent ECG monitoring lacks sufficient sensitivity to detect asymptomatic AF recurrence effectively.
Objective:
To compare the recurrence rates of atrial tachyarrhythmias between a 1-day monitoring group and a 14-day monitoring group using MEMO Patch 2 after catheter ablation in AF patients. The study also evaluates the effectiveness and safety of early recurrence detection via remote monitoring.
Study Population:
Patients diagnosed with AF and treated with catheter ablation.
Intervention:
Participants will undergo three sessions of remote ECG monitoring using MEMO Patch 2 and MEMO Link (first session only), spanning approximately one year after catheter ablation.
Hypothesis:
Long-term monitoring with MEMO Patch 2 will be more effective than 1-day monitoring in detecting the recurrence of atrial tachyarrhythmias (including AF, atrial flutter, and atrial tachycardia) following catheter ablation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental Group | Experimental | Participants in this clinical trial will undergo a total of three remote electrocardiographic (ECG) monitoring sessions during the study period following catheter ablation:
|
|
| Active Comparator Group | Active Comparator | Participants in this clinical trial will undergo a total of three remote electrocardiographic (ECG) monitoring sessions during the study period following catheter ablation:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MEMO Patch 2 - 14-day Monitoring | Device | A wearable ECG monitoring device used for continuous 14-day monitoring to detect atrial arrhythmias during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to assess early recurrence of atrial arrhythmias. |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence rate of atrial tachyarrhythmias 3 months post-catheter ablation | The proportion of participants with atrial tachyarrhythmias (including atrial fibrillation, atrial flutter, or atrial tachycardia lasting 30 seconds or more) detected during ECG monitoring at 3 months after catheter ablation using the MEMO Patch 2. The primary measure focuses on comparing the detection rate between the 14-day monitoring group and the 1-day monitoring group. | 3 months post-ablation |
| Measure | Description | Time Frame |
|---|---|---|
| Risk Factors for Early and Late Recurrence of Atrial Tachyarrhythmias | Identification of clinical risk factors associated with early recurrence (within 3 months) and late recurrence (beyond 3 months) of atrial tachyarrhythmias following catheter ablation, using data collected through MEMO Patch 2 monitoring. | 12 months post-ablation |
Not provided
Inclusion Criteria:
1. Adults aged 19 years or older who have voluntarily provided written informed consent to participate in this clinical trial.
2. Individuals who have been diagnosed with atrial fibrillation prior to the date of informed consent acquisition.
3. Individuals who are scheduled to undergo catheter ablation for atrial fibrillation within three months from the date of informed consent acquisition.
Exclusion Criteria:
1. Individuals with a history of catheter ablation prior to obtaining informed consent.
2. Individuals with sensitive skin, allergic skin conditions, skin cancer, rashes, or other dermatological disorders.
3. Individuals with implanted cardiac devices, such as pacemakers, implantable defibrillators, or other implantable electronic devices.
4. Individuals deemed by the investigator to be at an increased risk or otherwise unsuitable for participation in the clinical trial.
5. Individuals with cognitive impairments that make it difficult to understand trial information or voluntarily make an informed decision.
6. Pregnant or breastfeeding women.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jong-il Choi | Contact | +821021225476 | stabler92@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dong-A University Hospital | Busan | 49201 | South Korea |
De-identified individual participant data, including basic demographic data and primary research outcome data, will be shared. These data will specifically pertain to research conducted on remote monitoring and atrial fibrillation. The shared data will not contain any personal identifiers to ensure participant
When the data are made available, a direct link to the external repository hosting the IPD will be provided in the References module of the Protocol Section on ClinicalTrials.gov.
Not provided
Not provided
Qualified researchers may request access to the IPD by submitting a formal application. Requests must include a detailed research proposal and evidence of ethical approval. All requests will be reviewed by an independent committee to ensure appropriate and ethical use of the data. Once a suitable data-sharing platform or repository is designated, detailed instructions for access will be provided in the ClinicalTrials.gov record.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| MEMO Patch 2 - 1-day Monitoring | Device | A wearable ECG monitoring device used for 1-day monitoring during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to detect early recurrence of atrial arrhythmias. |
|
| MEMO Link | Device | A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session. |
|
| Rate of Medical Interventions Following Catheter Ablation |
Proportion of participants requiring additional medical interventions such as anti-arrhythmic drug cessation, repeat ablation procedures, or unplanned clinical visits post-ablation. |
| 12 months post-ablation |
| Recurrence Rate of Atrial Tachyarrhythmias at 12 Months | Proportion of participants experiencing atrial tachyarrhythmias (lasting 30 seconds or more) detected by MEMO Patch 2 within 12 months after catheter ablation. | 12 months post-ablation |
| Early Recurrence Rate of Atrial Tachyarrhythmias | Proportion of participants with atrial tachyarrhythmias detected within 3 months post-ablation using MEMO Patch 2. | 3 months post-ablation |
| Detection Rate of Non-Atrial Tachyarrhythmias Using MEMO Patch 2 | Proportion of participants with non-atrial tachyarrhythmias, such as ventricular premature contractions or supraventricular tachycardia, detected during MEMO Patch 2 monitoring. | 12 months post-ablation |
| Time to First Recurrence of Atrial Tachyarrhythmias | The time interval from catheter ablation to the first detection of atrial tachyarrhythmias lasting 30 seconds or more during MEMO Patch 2 monitoring. | 12 months post-ablation |
| ECG Signal Transmission Success Rate Using MEMO Link | Percentage of successfully transmitted ECG signals during the monitoring period using the MEMO Link device. | During all monitoring periods (up to 12 months post-ablation) |
| Detection Rate of Atrial Tachyarrhythmias in Daily Monitoring Reports | Proportion of participants with atrial tachyarrhythmias detected using daily ECG monitoring reports during the first monitoring phase (up to 30 days post-ablation). | 30 days post-ablation (first monitoring phase) |
| Device-Related Adverse Events | Rate of adverse events potentially related to the use of MEMO Patch 2 or MEMO Link during the study period, assessed through investigator reports. | During all monitoring periods (up to 12 months post-ablation) |
| Busan National University Hospital | Busan | 49241 | South Korea |
|
| Seoul National University Bundang Hospital | Seongnam | 13620 | South Korea |
|
| Korea University Anam Hospital | Seoul | 02855 | South Korea |
|
| Asan Medical Center | Seoul | 05505 | South Korea |
|
| Ewha Womans University Seoul Hospital | Seoul | 07804 | South Korea |
|
| Korea University Guro Hospital | Seoul | 08308 | South Korea |
|
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided